A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
Primary Purpose
Head and Neck Cancer
Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
[F-18] HX4
Sponsored by
About this trial
This is an interventional diagnostic trial for Head and Neck Cancer focused on measuring Newly Diagnosed, Head and Neck Cancer, PET Imaging
Eligibility Criteria
Inclusion Criteria:
- Patient is >18 years and male or female of any race / ethnicity.
- Patient or patient's legally acceptable representative provides written inform consent Patient is willing and able to comply with protocol procedures.
- Patient has newly diagnosed histologically confirmed squamous cell carcinoma of the head and/or neck whose primary origin is from the oral cavity, oropharynx, hypopharynx, larynx or nasopharynx.
- Patient is scheduled to have or already has had a clinical [F-18]FDG PET/CT scan prior (recommended to be within 14 days prior) to the [F-18]HX4 PET/CT scan.
- Patient has a primary tumor ≥ 2.0 cm in longest axis measured by CT or MR; or lymph node ≥ 2.0 cm in shortest axis measured by CT or MR if primary tumor < 2 cm on CT or MR; CT may be part of required [F-18]FDG PET/CT scan or a separate pre-surgery CT scan.
- Patient is scheduled to undergo complete tumor resection within 7 days for his/her cancer care after the [F-18]HX4 PET/CT scan is performed.
- Patient has not had nor will have neoadjuvant treatment, including radiation and chemotherapy, prior to patient's planned tumor resection.
Exclusion Criteria:
- Female patient is pregnant or nursing.
- Patient is not capable of remaining still for duration of imaging procedure (~ 4 hours).
- Patient has undergone an investigative, radioactive research procedure within 7 days prior to study participation, or is scheduled to undergo such a procedure during the study participation period.
- Patient has chronic renal function failure or is on renal dialysis
- Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data.
Sites / Locations
- University of Iowa Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
[F-18] HX4
Arm Description
Outcomes
Primary Outcome Measures
Serial measures of T/B Ratios and other imaging parameters
Serial measures of T/B ratios and other imaging parameters derived from the course imaging data of head and neck cancer pateitns in order to determine time of optimal imaging.
Secondary Outcome Measures
Correlations between T/B ratios of [F-18]HX4 uptake from pre-surgery PET imaging and immunohistochemistry measurements
Correlations between T/B ratios of [F-18]HX4 uptake from pre-surgery PET imaging and immunohistochemistry measurements obtained from surgical tumor samples
Kinetic Modeling Analysis
Kinetic parameters obtained from modeling time course of PET imaging data following [F-18]HX4 administration
Safety Assessments
Safety measurements including incidence of adverse events, and pre- and post-drug clinical laboratory measurements, vital signs and electrocardiograms
Full Information
NCT ID
NCT01506427
First Posted
December 28, 2011
Last Updated
December 12, 2012
Sponsor
Siemens Molecular Imaging
1. Study Identification
Unique Protocol Identification Number
NCT01506427
Brief Title
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
Official Title
A Phase I/II, Open Label, Nonrandomized, Multi-Center Study of [F-18]HX4 Positron Emission Tomography (PET) in Head and Neck Cancer Patients
Study Type
Interventional
2. Study Status
Record Verification Date
December 2012
Overall Recruitment Status
Withdrawn
Study Start Date
September 2012 (undefined)
Primary Completion Date
April 2013 (Anticipated)
Study Completion Date
June 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Siemens Molecular Imaging
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after [F-18] HX4 injection. This study will provide guidance for future studies involving [F-18]HX4 in cancer patients.
Detailed Description
Each consented patient will have a single administration of [F-18]HX4 and will immediately undergo one list mode PET/CT imaging session lasting 60 minutes followed by three additional list mode PET/CT acquisitions from 90 to 110 minutes, 150 to 170 minutes and 220 to 250 minutes after administration. The start times of the last three image acquisitions are permitted to be within ± 5 minutes. Venous blood samples will be collected throughout the initial scan sequence and at the time of each subsequent acquisition for calibration and metabolite-correction of the image-derived input function. On the day of administration (Visit 2) blood for clinical safety evaluations will be drawn pre- and post-dosing after all imaging is complete.
The pre-surgery [F-18]FDG PET/CT clinical scan performed prior to the [F-18]HX4 procedure, and the surgery at Visit 3 are standard of care for the consented patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Cancer
Keywords
Newly Diagnosed, Head and Neck Cancer, PET Imaging
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
[F-18] HX4
Arm Type
Experimental
Intervention Type
Radiation
Intervention Name(s)
[F-18] HX4
Intervention Description
A single dose of 10 mCi, injected intravenously.
Primary Outcome Measure Information:
Title
Serial measures of T/B Ratios and other imaging parameters
Description
Serial measures of T/B ratios and other imaging parameters derived from the course imaging data of head and neck cancer pateitns in order to determine time of optimal imaging.
Time Frame
Approximately 1 month after patient imaging; comprehensive analysis will be concluded within 1 month after Last Patient Out
Secondary Outcome Measure Information:
Title
Correlations between T/B ratios of [F-18]HX4 uptake from pre-surgery PET imaging and immunohistochemistry measurements
Description
Correlations between T/B ratios of [F-18]HX4 uptake from pre-surgery PET imaging and immunohistochemistry measurements obtained from surgical tumor samples
Time Frame
Estimated analysis to occur 1 month after patient surgery
Title
Kinetic Modeling Analysis
Description
Kinetic parameters obtained from modeling time course of PET imaging data following [F-18]HX4 administration
Time Frame
Estimated to be 2 weeks after the Imaging Date (Visit 2)
Title
Safety Assessments
Description
Safety measurements including incidence of adverse events, and pre- and post-drug clinical laboratory measurements, vital signs and electrocardiograms
Time Frame
On average of 3 weeks (from Time of Signing Consent to 24 hours after the Imaging Date)
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is >18 years and male or female of any race / ethnicity.
Patient or patient's legally acceptable representative provides written inform consent Patient is willing and able to comply with protocol procedures.
Patient has newly diagnosed histologically confirmed squamous cell carcinoma of the head and/or neck whose primary origin is from the oral cavity, oropharynx, hypopharynx, larynx or nasopharynx.
Patient is scheduled to have or already has had a clinical [F-18]FDG PET/CT scan prior (recommended to be within 14 days prior) to the [F-18]HX4 PET/CT scan.
Patient has a primary tumor ≥ 2.0 cm in longest axis measured by CT or MR; or lymph node ≥ 2.0 cm in shortest axis measured by CT or MR if primary tumor < 2 cm on CT or MR; CT may be part of required [F-18]FDG PET/CT scan or a separate pre-surgery CT scan.
Patient is scheduled to undergo complete tumor resection within 7 days for his/her cancer care after the [F-18]HX4 PET/CT scan is performed.
Patient has not had nor will have neoadjuvant treatment, including radiation and chemotherapy, prior to patient's planned tumor resection.
Exclusion Criteria:
Female patient is pregnant or nursing.
Patient is not capable of remaining still for duration of imaging procedure (~ 4 hours).
Patient has undergone an investigative, radioactive research procedure within 7 days prior to study participation, or is scheduled to undergo such a procedure during the study participation period.
Patient has chronic renal function failure or is on renal dialysis
Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Buatti, MD
Organizational Affiliation
University of Iowa Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Edward Aten, MD
Organizational Affiliation
President, Certus International
Official's Role
Study Director
Facility Information:
Facility Name
University of Iowa Medical Center
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
We'll reach out to this number within 24 hrs